Baxter downgraded to Hold from Buy at Deutsche Bank Deutsche Bank downgraded Baxter citing valuation and potential competition to the company's Hemophilia/recombinant franchise. The firm keeps a $63 price target for shares.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.